NEW YORK – From its beginning as a diagnostic company with a focus on veterinary medicine, LexaGene has taken the path of many other firms since the pandemic began – transitioning technology and resources to detecting COVID-19 in humans.
With its MiQLab sample-to-answer RT-PCR system, the firm is seeking to differentiate itself from competitors with a platform that facilitates the use of customizable syndromic panels that can look for 27 targets.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
